Litigation

Recent Posts

N.J. Risperdal Jury Finds Diabetes Warning Lacking, But Drug Didn't Cause Disease
Posted on 17 Feb 2012 by Tom Moylan

NEW BRUNSWICK, N.J. - (Mealey's) A Risperdal personal injury trial ended Feb. 16 in a defense verdict for Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. after a New Jersey state court jury found that Janssen failed to warn about the... Read More

No New Trial In Actos MDL Bellwether Case, But Punitives Are Cut From $9 Billion To $36 Million
Posted on 29 Oct 2014 by Tom Moylan

LAFAYETTE, La. — (Mealey’s) Takeda Pharmaceutical Co. Ltd. and Eli Lilly and Co. will not get a new trial in the first Actos bladder cancer multidistrict litigation bellwether case, but a Louisiana federal judge on Oct. 27 reduced the $9 billion... Read More

6 Third-Party Payers Settle Zyprexa Claims For $4.5Million After Class Vacated
Posted on 13 Jan 2012 by Tom Moylan

BROOKLYN, N.Y. - (Mealey's) The Zyprexa multidistrict litigation judge on Jan. 12 approved a $4.5 million settlement between Eli Lilly and Co. and six third-party payers who had their Racketeer Influence and Corrupt Organizations Act (RICO) class... Read More

97 Federal Cases Alleging Cancer From Diabetes Drugs Centralized In MDL
Posted on 27 Aug 2013 by Tom Moylan

WASHINGTON, D.C. — (Mealey’s) Ninety-seven federal lawsuits in which plaintiffs allege that three incretin-based diabetes drugs caused their pancreatic cancer were centralized Aug. 26 by a federal judicial panel into a multidistrict litigation... Read More